Matthew Emmens - Net Worth and Insider Trading
Matthew Emmens Net Worth
The estimated net worth of Matthew Emmens is at least $79 Million dollars as of 2024-04-16. Matthew Emmens is the Director of Vertex Pharmaceuticals Inc and owns about 200,873 shares of Vertex Pharmaceuticals Inc (VRTX) stock worth over $79 Million. Details can be seen in Matthew Emmens's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Matthew Emmens has not made any transactions after 2012-11-16 and currently still holds the listed stock(s).
Transaction Summary of Matthew Emmens
Matthew Emmens Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew Emmens owns 3 companies in total, including Bristol-Myers Squibb Co (BMY) , Vertex Pharmaceuticals Inc (VRTX) , and Incyte Corp (INCY) .
Click here to see the complete history of Matthew Emmens’s form 4 insider trades.
Insider Ownership Summary of Matthew Emmens
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Co | 2017-02-21 | director |
| VRTX | Vertex Pharmaceuticals Inc | 2012-11-16 | director |
| INCY | Incyte Corp | 2006-05-23 | director |
Matthew Emmens Latest Holdings Summary
Matthew Emmens currently owns a total of 1 stock. Matthew Emmens owns 200,873 shares of Vertex Pharmaceuticals Inc (VRTX) as of November 16, 2012, with a value of $79 Million.
Latest Holdings of Matthew Emmens
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | 2012-11-16 | 200,873 | 394.49 | 79,242,410 |
Holding Weightings of Matthew Emmens
Matthew Emmens Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew Emmens has made a total of 0 transactions in Vertex Pharmaceuticals Inc (VRTX) over the past 5 years. The most-recent trade in Vertex Pharmaceuticals Inc is the sale of 10,850 shares on November 16, 2012, which brought Matthew Emmens around $453,096.
Insider Trading History of Matthew Emmens
- 1
Matthew Emmens Trading Performance
Matthew Emmens Ownership Network
Ownership Network List of Matthew Emmens
Ownership Network Relation of Matthew Emmens
Matthew Emmens Owned Company Details
What does Bristol-Myers Squibb Co do?
Who are the key executives at Bristol-Myers Squibb Co?
Matthew Emmens is the director of Bristol-Myers Squibb Co. Other key executives at Bristol-Myers Squibb Co include EVP & Chief Commercial Officer Christopher S. Boerner , EVP & Corporate Affairs Cari Gallman , and SVP & Human Resources Ann Powell Judge .
Bristol-Myers Squibb Co (BMY) Insider Trades Summary
Over the past 18 months, Matthew Emmens made no insider transaction in Bristol-Myers Squibb Co (BMY). Other recent insider transactions involving Bristol-Myers Squibb Co (BMY) include a net sale of 45,419 shares made by Ann Powell Judge , a net sale of 96,295 shares made by Rupert Vessey , and a net purchase of 5,071 shares made by Christopher S. Boerner .
In summary, during the past 3 months, insiders sold 0 shares of Bristol-Myers Squibb Co (BMY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 382,446 shares of Bristol-Myers Squibb Co (BMY) were sold and 13,571 shares were bought by its insiders, resulting in a net sale of 368,875 shares.
Bristol-Myers Squibb Co (BMY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Bristol-Myers Squibb Co Insider Transactions
Matthew Emmens Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew Emmens. You might contact Matthew Emmens via mailing address: C/o Vertex Pharmaceuticals Incorporated, 130 Waverly St., Attn: General Counsel, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
